about
Immunotherapy for lung cancer: advances and prospectsAntitumor Responses of Invariant Natural Killer T CellsNKT cell networks in the regulation of tumor immunityNatural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitisReciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential.Invariant natural killer T cells generated from human adult hematopoietic stem-progenitor cells are poly-functional.Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice.The Response of CD1d-Restricted Invariant NKT Cells to Microbial Pathogens and Their ProductsAdoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Chronic alcohol consumption inhibits melanoma growth but decreases the survival of mice immunized with tumor cell lysate and boosted with α-galactosylceramide.2015 Guidance on cancer immunotherapy development in early-phase clinical studies.Invariant NKT cells are resistant to circulating CD15+ myeloid-derived suppressor cells in patients with head and neck cancer.Tumor suppression in mice lacking GABARAP, an Atg8/LC3 family member implicated in autophagy, is associated with alterations in cytokine secretion and cell death.Transcription factor Bcl11b sustains iNKT1 and iNKT2 cell programs, restricts iNKT17 cell program, and governs iNKT cell survivalEscape from IFN-γ-dependent immunosurveillance in tumorigenesis.Clinical relevance of circulating mucosal-associated invariant T cell levels and their anti-cancer activity in patients with mucosal-associated cancer.Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases.Induced pluripotent stem cells: challenges and opportunities for cancer immunotherapy.T-cell-associated cellular immunotherapy for lung cancer.From the Deep Sea to Everywhere: Environmental Antigens for iNKT Cells.Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer.Lactic acid in tumor microenvironments causes dysfunction of NKT cells by interfering with mTOR signaling.Alterations in cellular metabolism modulate CD1d-mediated NKT-cell responses.Glycolipid activators of invariant NKT cells as vaccine adjuvants.Immunotherapeutic strategies targeting natural killer T cell responses in cancer.The Hypothesis of the Human iNKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia.In vivo dendritic cell targeting cellular vaccine induces CD4(+) Tfh cell-dependent antibody against influenza virus.Enhancement of Adjuvant Functions of Natural Killer T Cells Using Nanovector Delivery Systems: Application in Anticancer Immune Therapy.Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells.α-Galactosylceramide stimulates splenic lymphocyte proliferation in vitro and increases antibody production in vivo in late neonatal-age mice.Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells.Natural Killer T Cell-Targeted Immunotherapy Mediating Long-term Memory Responses and Strong Antitumor Activity.Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cellsAlpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.Human Pluripotent Stem Cells to Produce Cell-based Cancer Immunotherapy.Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine.Natural Killer T Cells: An Ecological Evolutionary Developmental Biology Perspective.Integration of oncogenes via Sleeping Beauty as a mouse model of HPV16+ Oral tumor and immunologic control.Innate immune cells for immunotherapy of autoimmune and cancer disorders.Diastereomer-specific quantification of bioactive hexosylceramides from bacteria and mammals.
P2860
Q26750617-320F6726-9893-4337-8AEB-C46C63B69C42Q26778648-45A7E596-8BDC-4A80-AAAA-FDF025D15F98Q26866223-9BB0B76D-16F5-4289-89AC-96A0CDD11A0FQ28085038-06B156F5-5B64-4337-8E5E-C016E8350F51Q33720359-6024ED1D-3FEA-4422-BAC3-8C0B1742D57FQ35085309-7D8D3140-5C48-4E2A-AC70-8DBE91FA922EQ35506478-98E1BACE-1099-43E1-83A7-2778C39D327AQ35600087-FF18D7E9-B3FF-4AD1-8F6C-DEB570EA1804Q35641721-1521CD20-E253-47BE-8628-3D5A4F4EF29DQ36016694-C3CCD08A-BB76-4740-BB64-49A16F58AB86Q36467378-2350A286-E3F1-470D-8B52-5FD83EAF7A49Q36746282-845B8090-6CAA-41D3-87A6-B9AA24A8579EQ36866484-C88132FB-CF39-4648-A6F2-9DF42975207FQ37086432-0ABFB75F-3EE8-46BE-B50B-D755783E63E8Q37618482-5AB459E9-4D23-4463-9315-935B81E3E4A8Q37689104-C51DEBAA-AEBE-441E-A065-5AB9DD77B523Q37721209-06BD31C9-E672-4A0D-B046-EE35A997A12FQ38214635-E3DDBDF3-430E-4F12-8096-9AA4D73BB66AQ38266198-6415A140-30FB-449A-BE8C-5BE4C5A44361Q38410637-049A96E8-BEDF-475B-A2F3-24DFD2C99BAEQ38456346-CB84D01B-431E-446F-9591-30B777AED66CQ38725344-92745596-5FFB-414D-B372-D9BA94D7C683Q38764629-EFDC15AA-6D8B-483F-BE27-8EC050CF7E3BQ38885794-F5C78F75-2867-4630-8586-FB16B6D46AE0Q38890717-3A03A7F6-BAF6-4F46-AD75-2F8A52A59214Q38990873-752C5482-EB30-4A7D-B154-76EF60566981Q40507213-8AE86EBB-65F6-40FD-A233-4FE22BAD890CQ41139823-335286C0-E88C-4040-9572-8967DFC67B17Q41174284-9BF0AAAE-6C23-4041-8E2A-6FCB00337F10Q41759021-76A74982-E12D-4BA7-964E-E57EEAA74706Q42258167-D36FBAAC-0E84-414D-8195-988D6C36CF5FQ42368030-D340277E-A2CB-4305-A7C9-6843E2AAFBA4Q42556477-CC30263E-4437-48C7-BF2F-F34FCFD7E883Q44851304-31DE9F21-BF8E-46B3-AF6F-CDC96D26AEA6Q46350666-03ED0317-DC49-4217-95D0-90C6FAF00FF6Q47193039-9F9BF539-E6AA-4692-B25A-A3CBC4E99413Q47221129-6BC20B78-69F0-4D62-B61F-DDB9B5532469Q47549568-E540B409-4348-4CD5-8756-5CC03447DDB8Q48316500-3425A2A5-A1BD-4CEE-AD15-585151380AC9Q48326911-9C50C62D-37F2-4BF7-BA0A-139EF2A116DD
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
NKT cells as an ideal anti-tumor immunotherapeutic
@en
NKT cells as an ideal anti-tumor immunotherapeutic.
@nl
type
label
NKT cells as an ideal anti-tumor immunotherapeutic
@en
NKT cells as an ideal anti-tumor immunotherapeutic.
@nl
prefLabel
NKT cells as an ideal anti-tumor immunotherapeutic
@en
NKT cells as an ideal anti-tumor immunotherapeutic.
@nl
P2093
P2860
P356
P1476
NKT cells as an ideal anti-tumor immunotherapeutic
@en
P2093
Kanako Shimizu
Masaru Taniguchi
Naoki Kunii
Shin-Ichiro Fujii
Shinichiro Motohashi
Yoshitaka Okamoto
P2860
P356
10.3389/FIMMU.2013.00409
P577
2013-12-02T00:00:00Z